SavedAdd your journal

Journals / Eurasian Journal of Medicine and Oncology / 2019 / Cilt: 3 - Sayı: 3

Effects of Megestrol Acetate on Adrenal Function and Survival in Cancer Patients

BURCU YAPAR TAŞKÖYLÜ
GÜZİN FİDAN YAYLALI
Gamze GÖKÖZ DOĞU
ATİKE GÖKÇEN DEMİRAY
SERKAN DEĞİRMENCİOĞLU
AHMET ERGİN
Pages
199–202
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There wasn’t any correlation between the basal cortisol, ACTH levels, any biochemical parameter and overall survival.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Megestrol acetate (MA) can induce significant secondary adrenal suppression.
📊
Key Findings & Data:Methods: Thirty-one patients (aged 48–83 years) who were receiving MA took part in this study.
💡
Conclusion & Impact:There wasn’t any correlation between the basal cortisol, ACTH levels, any biochemical parameter and overall survival.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: Megestrol acetate (MA) can induce significant secondary adrenal suppression. We designed this study to determine the extent of adrenal insufficiency in cancer patients receiving MA and whether ther was any predictive factor for this. Methods: Thirty-one patients (aged 48–83 years) who were receiving MA took part in this study. Serum concentrations of TSH, ACTH, free T4, cortisol were measuresd in samples obtained at 7 AM, at baseline and 1st month. Standart ACTH (250 mg) stimulation test was performed if cortisol levels were below 18 µg/dl at any time. Results: 1 month after drug initiation, 32% of patients were accepted as adrenal insufficient. There wasn’t any correlation between the basal cortisol, ACTH levels, any biochemical parameter and overall survival. There was negative correlation between 1 month cortisol levels and survival time (p=0.04) If cortisol levels were lower at month of theraphy survival time was longer. Cox regression analysis showed that patients having lower cortisol levels at first month had 98% lower risk of death compared to patients having higher cortisol levels (p=0.02: OR 0.12 (0.02-0.75)). Conclusion: It is important to evaluate adrenal functions especially during episodes of infection or after withdrawal of MA therapy since this may require prompt corticosteroid treatment.

🔖

Cite This Article

TAŞKÖYLÜ, B. Y., YAYLALI, G. F., DOĞU, G. G., DEMİRAY, A. G., DEĞİRMENCİOĞLU, S., ERGİN, A. (2019). Effects of Megestrol Acetate on Adrenal Function and Survival in Cancer Patients. Eurasian Journal of Medicine and Oncology, Cilt: 3 - Sayı: 3, 199–202. https://ajindex.com/articles/126118

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Lopez AP, Figuls MR, Cuchi GU, Berenstein EG, Almenar Pasies B, Balcells Alegre M, et al. Systematic review of megestrol acetate in treatment of anorexia-cachexia syndrome.J Pain Symptom Manage 2004;27:360–9
  2. Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2005;18:CD004310
  3. Loprinzi CL, Jensen MC, Jiany NS, Schaid DJ. Effect of megestrol acetate on the human pituitary-adrenal axis. Mayo Clin Proc 1992;67:1160–2
  4. Leinung M, Koller EA, Fossler MJ. Corticosteroid effects of megestrol acetate.Endocrinologist 1998;8:153–9
  5. Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M. Glucocorticoid-like activity of megestrol. Arch Intern Med 1997;157:1651–6
  6. Subramanians S, Goker H, Kanji A, Sweeney H. Clinical adrenal insufficiency in patients receiving megestrol therapy. Arch Intern Med 1997;157:1008–11
  7. Steer KA, Kurtz AB. Honour, J.W. Megestrol-induced Cushing’s syndrome. Clin Endocrinol (Oxf) 1995;42:91–3
  8. Lambert A,Mitchell R, Frost J, Robertson WR. A simple in vitro approach to the estimation of the biopotency of drugs affecting adrenal steroidogenesis. J Steroid Biochem 1985;23:235–8
  9. Kontula K, Paavonen T, Luukkainen T, Andersson LC.Binding of progestins to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes. Biochem Pharmacol 1983;32:1511–8
  10. Yeh SS, Schuster MW. Megestrol acetate in cachexia and anorexia. Int J Nanomedicine 2006;1:411–6
  11. Reuben DB, Hirsch SH, Zhou K, Greendale GA. The effects of megestrol acetate suspension for elderly patients with reduced appetite after hospitalization: A phase II randomized clinical trial. J Am Geriatr Soc 2005;53:970–5
  12. Naing KK, Dewar JA, Leese GP. Megestrol acetate therapy and secondary adrenal suppression. Cancer 1999;86:1044–9
  13. Ron IG, Soyfer V, Goldray D, Inbar MJ, Weisman Y. A low-dose adrenocorticotropin test reveals impaired adrenal function in cancer patients receiving megestrol acetate therapy. Eur J Cancer 2002;3811:1490–4
  14. Chidakel At Zweig SB, Schlosser JR, Homel P, Schappert JW, Fleckman AM. High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate. J Endocrinol Invest 2006;29:136–140
  15. Rowland KM, Loprinzi CL, Shaw EG. Randomized doubleblind placebo controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small